TD Cowen lowered the firm’s price target on Agilon Health (AGL) to $2 from $6 and keeps a Hold rating on the shares. The firm updated its model following Q3 results and believes intermediate liquidity concerns are now a potential risk as is additional physician partner attrition.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health price target lowered to $2 from $5 at Barclays
- Agilon Health downgraded to Market Perform from Outperform at JMP Securities
- Agilon Health price target lowered to $2 from $4 at Deutsche Bank
- Agilon Health downgraded to Market Perform from Outperform at William Blair
- Agilon Health Reports Growth Amidst Financial Challenges